Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2–5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oxidative medicine and cellular longevity 2020, Vol.2020 (2020), p.1-29
Hauptverfasser: Silva, Filomena S. G., Saso, Luciano, Firuzi, Omidreza, Mendes, Catarina, Montezinho, Liliana, Cunha-Oliveira, Teresa, Oliveira, Paulo J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 29
container_issue 2020
container_start_page 1
container_title Oxidative medicine and cellular longevity
container_volume 2020
creator Silva, Filomena S. G.
Saso, Luciano
Firuzi, Omidreza
Mendes, Catarina
Montezinho, Liliana
Cunha-Oliveira, Teresa
Oliveira, Paulo J.
description Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2–5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.
doi_str_mv 10.1155/2020/5021694
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7683149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2465231886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-81646aeb03f6c5a4fdee07c9641f84063bcf14ca995978b6ba4aa7158af3efa73</originalsourceid><addsrcrecordid>eNqNkUtr3DAURk1paR7trusi6KbQTKKXZauLQghtGhiYQNq1uJblWMGWXEmedv59NMx0-lhlJcE9HOm7X1G8IfickLK8oJjiixJTIiR_VhwTyekCS8mfH-4YHxUnMT5gLBjl5GVxxBitOMb0uJhXv2wLya4NukvBxIisQ5fjxqfgp95qtIRkAgzoTg8m-GjjR3QLqc_DTbR-8PcbBK5Fq2nyIc3OJmsi6nxAtz2EEfQWsToLblwWrY1L1rtXxYsOhmhe78_T4vuXz9-uvi6Wq-ubq8vlQpesSouaCC7ANJh1QpfAu9YYXGkpOOlqntM0uiNcg5SlrOpGNMABKlLW0DHTQcVOi0877zQ3o2l1fj1nUVOwI4SN8mDVvxNne3Xv16oSNSNcZsH7vSD4H7OJSY02ajMM4Iyfo6JcVILImuGMvvsPffBzcDneliopI3UtMnW2o3ReZgymO3yGYLXtU237VPs-M_727wAH-HeBGfiwA3rrWvhpn6gzmckb-kNTzIWs2COchbUx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2465231886</pqid></control><display><type>article</type><title>Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Silva, Filomena S. G. ; Saso, Luciano ; Firuzi, Omidreza ; Mendes, Catarina ; Montezinho, Liliana ; Cunha-Oliveira, Teresa ; Oliveira, Paulo J.</creator><contributor>Quiles, Jos L.</contributor><creatorcontrib>Silva, Filomena S. G. ; Saso, Luciano ; Firuzi, Omidreza ; Mendes, Catarina ; Montezinho, Liliana ; Cunha-Oliveira, Teresa ; Oliveira, Paulo J. ; Quiles, Jos L.</creatorcontrib><description>Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2–5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.</description><identifier>ISSN: 1942-0900</identifier><identifier>EISSN: 1942-0994</identifier><identifier>DOI: 10.1155/2020/5021694</identifier><identifier>PMID: 33274002</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Age ; Amyotrophic lateral sclerosis ; Amyotrophic Lateral Sclerosis - drug therapy ; Amyotrophic Lateral Sclerosis - metabolism ; Amyotrophic Lateral Sclerosis - pathology ; Animals ; Antioxidants ; Antioxidants - therapeutic use ; Dehydrogenases ; Disease Models, Animal ; Enzymes ; Humans ; Life expectancy ; Mitochondria ; Motor Neurons - metabolism ; Motor Neurons - pathology ; Mutation ; Neurodegeneration ; Neurons ; Neuroprotective Agents - therapeutic use ; Oxidative stress ; Oxidative Stress - drug effects ; Proteins ; Reactive oxygen species ; Review ; Risk factors ; Spinal cord</subject><ispartof>Oxidative medicine and cellular longevity, 2020, Vol.2020 (2020), p.1-29</ispartof><rights>Copyright © 2020 Teresa Cunha-Oliveira et al.</rights><rights>Copyright © 2020 Teresa Cunha-Oliveira et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Teresa Cunha-Oliveira et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-81646aeb03f6c5a4fdee07c9641f84063bcf14ca995978b6ba4aa7158af3efa73</citedby><cites>FETCH-LOGICAL-c537t-81646aeb03f6c5a4fdee07c9641f84063bcf14ca995978b6ba4aa7158af3efa73</cites><orcidid>0000-0002-7382-0339 ; 0000-0003-4530-8706 ; 0000-0002-6877-4286 ; 0000-0002-5201-9948 ; 0000-0001-7143-8905 ; 0000-0002-2248-5198</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683149/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683149/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33274002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Quiles, Jos L.</contributor><creatorcontrib>Silva, Filomena S. G.</creatorcontrib><creatorcontrib>Saso, Luciano</creatorcontrib><creatorcontrib>Firuzi, Omidreza</creatorcontrib><creatorcontrib>Mendes, Catarina</creatorcontrib><creatorcontrib>Montezinho, Liliana</creatorcontrib><creatorcontrib>Cunha-Oliveira, Teresa</creatorcontrib><creatorcontrib>Oliveira, Paulo J.</creatorcontrib><title>Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention</title><title>Oxidative medicine and cellular longevity</title><addtitle>Oxid Med Cell Longev</addtitle><description>Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2–5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.</description><subject>Age</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Amyotrophic Lateral Sclerosis - drug therapy</subject><subject>Amyotrophic Lateral Sclerosis - metabolism</subject><subject>Amyotrophic Lateral Sclerosis - pathology</subject><subject>Animals</subject><subject>Antioxidants</subject><subject>Antioxidants - therapeutic use</subject><subject>Dehydrogenases</subject><subject>Disease Models, Animal</subject><subject>Enzymes</subject><subject>Humans</subject><subject>Life expectancy</subject><subject>Mitochondria</subject><subject>Motor Neurons - metabolism</subject><subject>Motor Neurons - pathology</subject><subject>Mutation</subject><subject>Neurodegeneration</subject><subject>Neurons</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Proteins</subject><subject>Reactive oxygen species</subject><subject>Review</subject><subject>Risk factors</subject><subject>Spinal cord</subject><issn>1942-0900</issn><issn>1942-0994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkUtr3DAURk1paR7trusi6KbQTKKXZauLQghtGhiYQNq1uJblWMGWXEmedv59NMx0-lhlJcE9HOm7X1G8IfickLK8oJjiixJTIiR_VhwTyekCS8mfH-4YHxUnMT5gLBjl5GVxxBitOMb0uJhXv2wLya4NukvBxIisQ5fjxqfgp95qtIRkAgzoTg8m-GjjR3QLqc_DTbR-8PcbBK5Fq2nyIc3OJmsi6nxAtz2EEfQWsToLblwWrY1L1rtXxYsOhmhe78_T4vuXz9-uvi6Wq-ubq8vlQpesSouaCC7ANJh1QpfAu9YYXGkpOOlqntM0uiNcg5SlrOpGNMABKlLW0DHTQcVOi0877zQ3o2l1fj1nUVOwI4SN8mDVvxNne3Xv16oSNSNcZsH7vSD4H7OJSY02ajMM4Iyfo6JcVILImuGMvvsPffBzcDneliopI3UtMnW2o3ReZgymO3yGYLXtU237VPs-M_727wAH-HeBGfiwA3rrWvhpn6gzmckb-kNTzIWs2COchbUx</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Silva, Filomena S. G.</creator><creator>Saso, Luciano</creator><creator>Firuzi, Omidreza</creator><creator>Mendes, Catarina</creator><creator>Montezinho, Liliana</creator><creator>Cunha-Oliveira, Teresa</creator><creator>Oliveira, Paulo J.</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7382-0339</orcidid><orcidid>https://orcid.org/0000-0003-4530-8706</orcidid><orcidid>https://orcid.org/0000-0002-6877-4286</orcidid><orcidid>https://orcid.org/0000-0002-5201-9948</orcidid><orcidid>https://orcid.org/0000-0001-7143-8905</orcidid><orcidid>https://orcid.org/0000-0002-2248-5198</orcidid></search><sort><creationdate>2020</creationdate><title>Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention</title><author>Silva, Filomena S. G. ; Saso, Luciano ; Firuzi, Omidreza ; Mendes, Catarina ; Montezinho, Liliana ; Cunha-Oliveira, Teresa ; Oliveira, Paulo J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-81646aeb03f6c5a4fdee07c9641f84063bcf14ca995978b6ba4aa7158af3efa73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Amyotrophic Lateral Sclerosis - drug therapy</topic><topic>Amyotrophic Lateral Sclerosis - metabolism</topic><topic>Amyotrophic Lateral Sclerosis - pathology</topic><topic>Animals</topic><topic>Antioxidants</topic><topic>Antioxidants - therapeutic use</topic><topic>Dehydrogenases</topic><topic>Disease Models, Animal</topic><topic>Enzymes</topic><topic>Humans</topic><topic>Life expectancy</topic><topic>Mitochondria</topic><topic>Motor Neurons - metabolism</topic><topic>Motor Neurons - pathology</topic><topic>Mutation</topic><topic>Neurodegeneration</topic><topic>Neurons</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Proteins</topic><topic>Reactive oxygen species</topic><topic>Review</topic><topic>Risk factors</topic><topic>Spinal cord</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silva, Filomena S. G.</creatorcontrib><creatorcontrib>Saso, Luciano</creatorcontrib><creatorcontrib>Firuzi, Omidreza</creatorcontrib><creatorcontrib>Mendes, Catarina</creatorcontrib><creatorcontrib>Montezinho, Liliana</creatorcontrib><creatorcontrib>Cunha-Oliveira, Teresa</creatorcontrib><creatorcontrib>Oliveira, Paulo J.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxidative medicine and cellular longevity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silva, Filomena S. G.</au><au>Saso, Luciano</au><au>Firuzi, Omidreza</au><au>Mendes, Catarina</au><au>Montezinho, Liliana</au><au>Cunha-Oliveira, Teresa</au><au>Oliveira, Paulo J.</au><au>Quiles, Jos L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention</atitle><jtitle>Oxidative medicine and cellular longevity</jtitle><addtitle>Oxid Med Cell Longev</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>29</epage><pages>1-29</pages><issn>1942-0900</issn><eissn>1942-0994</eissn><abstract>Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2–5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>33274002</pmid><doi>10.1155/2020/5021694</doi><tpages>29</tpages><orcidid>https://orcid.org/0000-0002-7382-0339</orcidid><orcidid>https://orcid.org/0000-0003-4530-8706</orcidid><orcidid>https://orcid.org/0000-0002-6877-4286</orcidid><orcidid>https://orcid.org/0000-0002-5201-9948</orcidid><orcidid>https://orcid.org/0000-0001-7143-8905</orcidid><orcidid>https://orcid.org/0000-0002-2248-5198</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1942-0900
ispartof Oxidative medicine and cellular longevity, 2020, Vol.2020 (2020), p.1-29
issn 1942-0900
1942-0994
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7683149
source MEDLINE; Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
subjects Age
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - drug therapy
Amyotrophic Lateral Sclerosis - metabolism
Amyotrophic Lateral Sclerosis - pathology
Animals
Antioxidants
Antioxidants - therapeutic use
Dehydrogenases
Disease Models, Animal
Enzymes
Humans
Life expectancy
Mitochondria
Motor Neurons - metabolism
Motor Neurons - pathology
Mutation
Neurodegeneration
Neurons
Neuroprotective Agents - therapeutic use
Oxidative stress
Oxidative Stress - drug effects
Proteins
Reactive oxygen species
Review
Risk factors
Spinal cord
title Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T20%3A25%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxidative%20Stress%20in%20Amyotrophic%20Lateral%20Sclerosis:%20Pathophysiology%20and%20Opportunities%20for%20Pharmacological%20Intervention&rft.jtitle=Oxidative%20medicine%20and%20cellular%20longevity&rft.au=Silva,%20Filomena%20S.%20G.&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=29&rft.pages=1-29&rft.issn=1942-0900&rft.eissn=1942-0994&rft_id=info:doi/10.1155/2020/5021694&rft_dat=%3Cproquest_pubme%3E2465231886%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2465231886&rft_id=info:pmid/33274002&rfr_iscdi=true